Recon: PhRMA launches direct-to-consumer drug site; Shutdown would prompt HHS to furlough 41% of staff

• US lobby group PhRMA plans website to boost access to cheaper drugs (Reuters) (Bloomberg)
• White House's 'most favored nation' deadline spurs flurry of pharma concessions (Endpoints)
• US government shutdown to furlough 41% of health agency workers (Reuters)
• Trump to Face Off With Democrats Ahead of Shutdown Deadline (Bloomberg)
• Kala Bio plunges after scrapping development of lead drug (Reuters)

• AstraZeneca to list shares in New York while keeping London listing (STAT)
• AbbVie to launch ovarian cancer drug in UK at US price (Reuters)
• Germany assumes 15% U.S. tariff rate will apply to pharma, heavy trucks (Reuters)
• Bavarian Nordic Bidders Extend Offer Deadline, Maintain Price (Bloomberg)
• Egypt Flexes Export Muscle With Surging Dietary Supplement Trade (Bloomberg)
• MedTech Europe pressures EU to make regulatory changes by early 2026 (MedTech Dive)

• Perimenopause is the new buzzword in the business of women’s health (STAT)
• As investor for AHA, ‘Venture Valkyrie’ argues ‘good medicine is good business’ (STAT)
• Genmab to buy Merus in $8B deal (STAT)
• Lilly executives: How the FDA’s new PreCheck program can unleash the future of U.S. medicine manufacturing (STAT)
• MoonLake can’t spin away this disastrous autoimmune drug failure (STAT)
• GSK CEO Walmsley to step down, be succeeded by company’s commercial lead (STAT)
• Enanta's RSV treatment misses main goal in mid-stage study (Reuters)
• Larimar's update on Friedreich's ataxia drug derailed by allergic reactions (Endpoints)
• Tourmaline attracted small bidding war before $1.4B sale to Novartis (Endpoints)
• IO Biotech to run another study for cancer vaccine; Boehringer ends mid-stage IPF trial (Endpoints)

• Exclusive: Once a mental health chatbot, Wysa acquires physical therapy startup Kins (Endpoints)
• Prosthetics Firm Ottobock, Owner Seek €702 Million in IPO (Bloomberg)
• SS Innovations hires new CFO (MedTech Dive)
• Biolinq gets FDA de novo nod for intradermal glucose sensor (MedTech Dive)
• J&J’s Abiomed Issues Third Recall Of Automated Impella Controllers Since June (MedTech Insight)

• A matcha shortage is coming for social media’s latest obsession (Food Dive)
• Recall impacts corn dogs, sausage-on-a-stick products (The Hill)

• Cannabis stocks surge after Trump endorses cannabidiol for senior healthcare (Reuters)
• Bedside Upgrade: Glooko Pushes Into Hospitals With Monarch EndoTool Deal, Targeting $1Bn Market (MedTech Insight)
• Section 232 probe reignites tariff uncertainty for medtech firms (MedTech Dive)
• OIG Urges Reforms To Medicare Skin Substitute Payments (MedTech Insight)
• Supply of Birth Control Pills in the US at Risk as Tariffs Kick In (Bloomberg)